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 
Abstract—Studies regarding the role of the complement system 
in parasitic infections have demonstrated that the complement 
system often fails to achieve the intended task of destroying the 
parasite. The reason for this failure is the development of efficient 
mechanisms for the parasites to evade attack or the subversion of 
the complement system (i.e., using components of the complement 
system to facilitate the infection progress). In this review, we 
intend to demonstrate the complexity of the interaction between 
parasites and the complement system in schistosomiasis mansoni, 
leishmaniases and malaria. The complement system is activated 
through the classical, alternative or lectin pathways, but in many 
circumstances, it facilitates infection, as occurs in leishmaniases, 
or exerts almost no protective effects against the parasite, as 
observed in schistosomiasis mansoni, due to the evasion 
mechanisms and biological characteristics of the parasite. In 
malaria, the complement system participates in erythrocyte 
invasion and, depending on the degree of activation, in different 
pathogenic mechanisms related to the uncomplicated or severe 
manifestations of malaria. This review is not comprehensive; 
however, we emphasize the systems and components necessary for 
an understanding of complement system-parasite interactions.  
 
Index Terms— complement system, evasion mechanisms, 
innate immunity, leishmaniasis, malaria, parasite, schistosomiasis 
 
I. INTRODUCTION 
HE complement system is a major player in innate 
immunity, and because complement is present in tissue 
fluids and in the blood, it encounters parasites immediately 
upon introduction into the host organism. Most of the initial 
studies on the role of complement in parasite infections have 
approached this system as an innate host component for 
controlling infection by inducing parasite killing, as the system 
has been long perceived. This perception is changing in many 
fields and types of infections. The development of studies 
examining the role of complement in parasitic infections has 
shown that the complement system fails in many ways to exert 
 
Submitted Feb 18, 2013 and accepted March 15, 2013 
Hiro Goto is with the Laboratorio de Soroepidemiologia e Imunobiologia, 
Instituto de Medicina Tropical de São Paulo, USP, São Paulo, Brazil and 
Departamento de Medicina Preventiva, Faculdade de Medicina da USP, São 
Paulo, Brazil. Address: Instituto de Medicina Tropical de São Paulo, Av. Dr. 
Enéas de Carvalho Aguiar 470, prédio II, 4° andar, 05403-000, São Paulo, SP, 
Brazil. Tel.: +55-11-30617023; Fax: +55-11-30618270 (e-mail: 
hgoto@usp.br). 
Maria Carmen Arroyo Sanchez is with the Laboratorio de 
Soroepidemiologia e Imunobiologia, Instituto de Medicina Tropical de São 
Paulo, USP, São Paulo, Brazil (e-mail: arroyo@usp.br). 
the intended function of parasite destruction. The reason for 
this failure is the development of efficient mechanisms for the 
parasites to evade complement attack or the subversion of this 
system (i.e., using components of the complement system to 
facilitate the infection process). 
In this review, we intend to convey the complexity of the 
interaction with the complement system, which can function to 
eliminate parasite function, to facilitate infection or to facilitate 
the pathogenesis of various disease manifestations. This review 
is not comprehensive; however, we emphasize the systems and 
components necessary for an understanding of complement 
system-parasite interactions, as exemplified by helminth and 
protozoan infections (see Boxes 1, 2 and 3 for information on 
the epidemiology, parasitic life cycle and clinical 
manifestations). 
Briefly, the complement system comprises more than 30 
plasma and membrane-associated proteins that interact in a 
cascade through the sequential activation of many proenzymes 
that catalyze the activation of other enzymes (reviewed in [1]). 
Several complement activation pathways have been described 
(reviewed in [2]). The classical (CP), alternative (AP) and 
mannose-binding lectin (MBL) pathways (Fig. 1) lead to the 
formation of the C3 convertases, which cleave C3 into C3b and 
C3a [3]. The classical pathway begins with the binding of the 
C1 complex, specifically the C1q fraction, usually to an 
antibody in the immune complex. C1q then sequentially 
activates the serine proteases C1r and C1s, which cleave C4 and 
C2 to generate the C4a, C4b, C2a and C2b fragments. The C4b 
and C2a fragments then form the C4b2a complex, which 
constitutes the C3 convertase of the classical pathway. The 
alternative pathway is activated regardless of the presence of an 
antibody when C3 reacts with a hydroxyl or amino group on the 
surface of a pathogen. The resulting surface-bound C3b forms 
C3bB with factor B. Factor D then cleaves factor B into Ba and 
Bb, and the latter associates with C3b to form C3bBb, which 
constitutes the C3 convertase of the alternative pathway. The 
lectin pathway is activated when mannose-binding lectin (MBL) 
binds to mannose on the pathogen surface. This pathway is 
similar to the classical pathway but acts in the absence of 
antibody. MBL, or alternatively ficolin, activates 
MBL-associated serine proteases 1 and 2 (MASP-1 and 
MASP-2). These MASPs cleave C4 and C2 similarly to C1r 
and C1s in the classical pathway, leading to the formation of the 
C3 convertase C4b2a. C3 is the main component of the 
complement system, and all three pathways with their 
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respective C3 convertases converge to promote the cleavage of 
C3 into C3a (chemotactic factor) and C3b. C3b with C3 
convertase then form the C5 convertase that cleaves C5, 
generating the C5a (chemotactic factor) and C5b fragments. 
Subsequently, the stepwise assembly of the components C5b, 
C6, C7, C8 and C9 is initiated, resulting in the formation of the 
membrane attack complex (MAC) C5b-C6-C7-C8-C9 [4]. The 
polymerized final components form a pore-like structure in the 
membrane, leading to the lysis of the targeted cells. There are 
two additional pathways that are independent of C3: the 
thrombin-mediated pathway, in which thrombin acts as a C5 
convertase [5], and the pathway in which activated neutrophils 
and macrophages secrete serine proteases that cleave C5 [6].  
 
 
Fig. 1.  The three Activation Pathways of Complement: the Classical, the 
Mannose-Binding Lectin, and the Alternative Pathways.  
The classical pathway begins with the binding of the C1 complex (which 
consists of C1q, two molecules of C1r, and two molecules of C1s) to antibodies 
(Ab) in the immune complex (the classical pathway may also be activated by 
apoptotic cells, certain viruses and gram-negative bacteria and C-reactive 
protein bound to ligand). C1s sequentially cleaves C4 and C2, leading to the 
formation of the C4b2a enzyme complex, the C3 convertase of the classical 
pathway. The lectin pathway is initiated by binding of the complex of 
mannose-binding lectin (MBL) and the serine proteases M–associated 
proteases 1 and 2 (MASP1 and MASP2, respectively) to mannose groups on the 
surface of a bacterial cell. MASPs cleave C4 and C2, leading to the formation 
of the C3 convertase enzyme C4b2a. The alternative pathway is activated by 
many bacteria, fungi, viruses and tumor cells. This pathway is activated by 
cleavage of C3 in plasma. The resulting C3b binds covalently to hydroxyl 
groups on cell-surface carbohydrates and proteins and then binds to factor B to 
form the C3bB complex. Factor D cleaves factor B bound to C3b to form the 
complex C3bBb, the alternative pathway C3 convertase. The three pathways 
lead to the formation of C3 convertase enzymes, which cleave C3 into C3b and 
C3a fragments. C3b binds to the C3 convertase enzymes, forming C5 
convertase enzymes, which cleave C5, generating C5a and C5b fragments. The 
C5b fragment initiates the stepwise assembly of the components C6, C7, C8, 
and C9, resulting in the formation of the membrane-attack complex (MAC), 
C5b-C6C7C8C9n. (reviewed in [152]). 
The resultant fragments and the complex define the main 
functions of the complement system in the innate immune 
response, which are as follows [1]: 1) membrane lysis through 
the assembly of the membrane attack complex (MAC), which 
leads to the formation of membrane pores; 2) inflammation due 
to the generation of the potent pro-inflammatory 
anaphylatoxins C3a, C4a, and C5a, which bind to their 
respective receptors expressed on macrophages, neutrophils, 
basophils, eosinophils, mast cells and some dendritic cells; and 
3) the opsonization and clearance of opsonized elements 
through the C4b, C3b, and C3bi fragments, which can bind to 
complement receptors on phagocytic cells. 
Due to the destructive potential of complement activation, 
the complement cascade is regulated by several proteins in the 
plasma and on the cell surface [7] to prevent autologous 
complement attacks [1]. The regulators include membrane 
cofactor protein (MCP or CD46), decay-accelerating factor 
(DAF or CD55), membrane inhibitor of reactive lysis (MIRL or 
CD59) and complement receptor 1 (CR1 or CD35) (reviewed in 
[8]). CR1, CD55, and MCP are members of the regulators of 
complement activation (RCA) protein family [8]. CR1, CD55, 
and CD59 are found on the erythrocyte surface and are 
responsible for the complement-regulatory properties of these 
cells [9]. Erythrocytes account for more than 85% of the CR1 in 
the blood [10].  
In humans, the number of CR1 molecules expressed on 
erythrocytes varies between individuals within a range of 
50–1200 molecules per cell [11]. Various single nucleotide 
polymorphisms (SNPs) of the CR1 gene are associated with 
variations in the expression levels of erythrocyte CR1 [12] [13].  
CR1 plays essential roles in mammalian immunity. It is 
responsible for the complement-regulatory properties of the 
erythrocyte surface [9]. CR1 has decay-accelerating activity for 
C3- and C5-convertases [14], limiting the deposition of C3b 
and C4b and subsequent excessive complement activation [15]. 
CR1 acts as a cofactor in the factor I-mediated cleavage of C3b 
and C4b to iC3b and iC4b, respectively [16]. This activity is 
thought to play an important role in limiting the activation of 
the pathway. The expression of CR1 on human erythrocytes is 
believed to provide an important clearance function. On 
erythrocytes, CR1 is an immune-adherence receptor that binds 
to C3b/C4b-opsonized immune complexes and transports them 
to the spleen and liver for removal [17]. On phagocytic cells, 
the interaction between the complement receptor and C3bi, 
together with the binding of C3b to CR1, which is also present 
on phagocytes, promotes the adherence and phagocytosis of 
antigens in the liver and spleen [15].  
When C3b is uniformly distributed over the erythrocyte 
surface, CR1 can diffuse through the erythrocyte membrane, 
interacting with deposited C3b; CR1 also diffuses on 
neutrophils and lymphocytes [18]. 
Another function of CR1 is the retention of opsonized 
antigens necessary to maintain immunological memory on 
follicular dendritic cells in germinal centers [15] [19].  
CD55 and CD59 are erythrocyte surface proteins that also 
have important roles in protecting erythrocytes from 
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complement activation by promoting the inactivation of C3 
convertases (CD55) and interfering with the assembly of the 
MAC C5b-9 (CD59) [20]. 
II. THE COMPLEMENT SYSTEM IN SCHISTOSOMIASIS MANSONI  
During the life cycle within the vertebrate host, Schistosoma 
mansoni induces a variety of innate and acquired immune 
responses. However, this parasite not only survives these 
numerous attacks but also lives in hostile environments for 
years and decades using different mechanisms to evade the 
immune response (reviewed in [21]). Because the cercariae are 
the first form that the host copes with, the innate elements are 
the main players of the immune response. Innate elements also 
affect other forms, but the acquired immune response is 
induced by schistosomula, adult worms and eggs in the tissues, 
which are targets of acquired humoral and cell-mediated 
mechanisms [22]. Antibody-dependent, cell-mediated 
cytotoxicity is considered an important defense mechanism 
against schistosomula, which involves IgG and IgE antibodies 
and various cell types, including T cells, eosinophils and 
neutrophils [23] [24]. The cell-mediated immune response is 
important against eggs in tissues, leading to granuloma 
formation and regulation [25]. Recently in the field of  vaccine 
development, a discussion has been ongoing regarding the 
parasite life cycle phase that should be targeted, the vulnerable 
structures, and the identity of relevant immunogenic molecules; 
in this discussion, in vitro and in vivo data from different 
animal models are being critically considered [21]. 
One of the potent innate elements of the immune system that 
the Schistosoma must face is the complement system, which 
also functions as an effector of the acquired humoral immune 
response. Cercariae [26], schistosomula [27] [28] [29] [30], and 
adult worms [31] [32] activate the alternative pathway in vitro. 
MBL was shown to adhere to surface glycoproteins of cercariae 
and adult worms [33], but in MBL knock-out mice, the course 
of infection was not altered, raising questions about its 
biological relevance [34]. In terms of complement activation by 
the classical pathway, there are data demonstrating the presence 
of various immunoglobulin classes and subclasses on the 
Schistosoma surface that may activate the classical complement 
pathway [35]. Recently, a proteomic analysis confirmed the 
deposition of different host immunoglobulin classes and 
subclasses and the further presence of the complement C3 
fraction fragments C3c/C3dg [36] [37], indicating the 
activation of complement at the parasite surface.  
To evade complement attack, Schistosoma mansoni presents 
various mechanisms that are persistent throughout the life cycle, 
in addition to the parasite constituents that are inherently 
appropriate for life in a hostile environment. An initial 
alteration that the cercariae manifest within the host during 
differentiation into the schistosomulum is the shedding of the 
surface membrane glycocalyx, which is a potent activator of the 
alternate complement pathway [28]. Concomitantly, the 
parasite acquires a tegument, which is a syncytium composed 
of a plasma membrane with an overlaid membrane-like 
secretion known as membranocalyx [38] [39]. This change is 
important for evasion because the membranocalyx is weakly 
immunogenic, can avoid the exposure of parasite molecules 
present in the plasma membrane, and can take up various host 
molecules to disguise the parasite as ‘self’ within the host [40]. 
Membranocalyx was believed to undergo rapid turnover to 
avoid the fixation of the MAC of the complement system, but 
data that are more recent indicate that the turnover is not rapid 
enough to block fixation [40]. Possibly related to the 
characteristics of the adult worm membrane, which should be 
better characterized, an intriguing observation was that almost 
no inflammation was found around the parasite in vessels of 
CBA and BALB/c mouse strains and in samples from 
chimpanzees, although inflammation was evident in other 
tissues around the eggs [41].  
Another constituent facilitating evasion is the presence of the 
Fc receptor detected on the surface of adult Schistosoma 
mansoni [42], which is similar to the paramyosin molecule. 
This receptor presumably captures immunoglobulin via the Fc 
domain, thus disabling the C1q binding [43]. Another molecule 
with similarity to paramyosin is schistosome complement 
inhibitory protein-1 (SCIP-1) [44], which is also similar to 
human complement inhibitor protein CD59, which can bind C8 
and C9 and circumvent cell lysis [45]. The existence and 
localization of paramyosin in Schistosoma mansoni is 
controversial [35]; furthermore, a recent proteomic analysis did 
not confirm the presence of the paramyosin molecule on the 
Schistosoma mansoni surface [36]. Notably, however, a paucity 
of immunoglobulin deposits were detected on the parasite [42], 
which may indicate the scarcity of exposed parasite antigen in 
the tegument, seemingly situated at the plasma membrane [36]. 
This low amount of bound immunoglobulins may be more 
relevant for evasion than for the putative role of the Fc receptor 
and paramyosin in the inactivation of complement attack. 
Schistosomes have some regulatory molecules that inhibit 
the activation of the complement cascade. One known 
regulatory protein is CRIT (complement C2 receptor inhibiting 
trispanning), also known as Schistosoma trispanning orphan 
receptor [46], which functions as a receptor for the C2 protein 
and is shown to inhibit the activation of the classical pathway 
[47] [48]. In a proteomic analysis of parasite surface 
membranes, this molecule was not detected [36], but the 
SmTOR gene was identified in another study, and its structure 
was analyzed. It was suggested that the receptor is 
tetraspanning instead of trispanning (however, keeping the 
same abbreviation TOR), and the protein was detected in adult 
worm extracts but was mainly found on the cercariae surface 
[46]. 
A critical component of complement activation is the C3 
protein, and in Schistosome, a C3-binding molecule was 
detected, and its production by the parasite confirmed [49]. 
This protein would interfere with complement activation, but 
its existence is controversial, and the molecule remains 
uncharacterized [40].  
Schistosomes also acquire some molecules from the host that 
may contribute to evasion. One such protein is DAF, which 
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protects the schistosomula from antibody-mediated lysis [50]. 
However, this protein was not detected by proteomic analysis 
of the adult parasite extract [36]. Complement receptor-related 
protein y (Crry) was also identified, which inactivates the 
C3-derived fragments, by proteomic analysis of the adult 
schistosome extract [36]. 
It is worth mentioning that most of the data were derived 
from in vitro observations. In C3-deficient mice [51], no 
significant difference was observed compared with the 
wild-type controls. However, in C5-deficient mice, when cobra 
venom factor (CVF) was used to deplete complement, the 
worm burden was higher [52], suggesting in vivo a role for the 
alternative pathway in protection from pathogens. 
From the above-described data, we conclude that the 
Schistosoma uses so many tricks and constitutive components 
to evade complement attack that the presence or absence of 
complement activation appears to exert only a marginal effect 
on the parasite. 
III. THE COMPLEMENT SYSTEM IN LEISHMANIASES 
As soon as the Leishmania promastigotes are injected by 
phlebotomine sandflies into the skin, the parasite comes into 
contact with the complement system. Most Leishmania species, 
such as Leishmania major, L. enrietti, L. mexicana, L. 
amazonensis, and L. braziliensis, activate the alternative 
complement pathway [53] [54]. In contrast, L. donovani 
appears to activate the classical pathway [54] [55], suggesting 
the participation of natural antibodies. However, because L. 
major, L. Mexicana, and L. braziliensis promastigotes bind to 
mannan [56] [57], the activation of the lectin pathway must also 
be considered [58] [59]. Nonetheless, in experiments under 
more physiological conditions using whole blood or high serum 
concentrations, the importance of natural antibodies and the 
classical pathway has been reconsidered, and the participation 
of classical pathway has also extended to other Leishmania 
species [60] [61].  
Regardless of the pathway used, C3b deposition on the 
surface of the parasite constitutes a crucial step in complement 
activation that may proceed either with the formation of C5 
convertase with the subsequent formation of membrane attack 
complex C5b-C9 implicated in parasite lysis or with its 
inactivation by generating iC3b. The most abundant molecules 
on the Leishmania surface, gp63 (also called membrane surface 
protease) [62] and lipophosphoglycan (LPG) [63], have been 
identified as C3 acceptors. These molecules have been much 
studied [64] [65] and has been shown to participate in different 
processes during the life cycle.  
Promastigotes become infectious within the insect when they 
reach the stationary phase of growth and turn into metacyclic 
forms [66] that are also more resistant to lysis by complement 
[67]. This resistance to lysis was attributed to the modification 
of LPG, which becomes longer at this stage [64] and blocks the 
binding of MAC to the parasite membrane [68]. The expression 
of gp63 is also increased in the metacyclic form [69], and as a 
protease, it accelerates the conversion of C3b to iC3b, 
hindering the formation of MAC [70]. Another factor is protein 
kinase C, which exhibits increased expression in the metacyclic 
form and phosphorylates several components of the 
complement system, such as C3, C5, and C9 [71], to block the 
activation of the classical and alternative pathways. 
Most studies in the literature have used promastigotes, but L. 
donovani amastigotes were initially considered nonsusceptible 
to lysis by complement [55]; however, they have since been 
shown to be susceptible but to a much lesser extent [72]. 
Another consequence of complement activation is the 
generation of the chemotactic fragments C3a and C5a, which 
promote tissue inflammation by attracting polymorphonuclear 
neutrophils and monocytes/macrophages to the site of infection. 
Recently, another mechanism of the migration of effector 
macrophages to the L. major infection site was shown to be 
initiated by complement activation, which causes the binding of 
platelets to L. major, leading to the release of PDGF, which 
induces CCL2 (MCP-1). It was demonstrated that these effector 
macrophages efficiently kill the parasites at the early phase of 
infection [73].  
Macrophages phagocytose Leishmanias that engage various 
membrane receptors, such as fibronectin, mannose, b-glucan, 
and complement receptor 1 (CR1) and 3 (CR3) [74]. The 
receptors involved in the interactions between macrophages 
and amastigotes have not been extensively studied, but the CR3 
and Fc receptors are considered important [75] [76]. The 
parasite LPG, gp63, and advanced glycosylation products 
participate in this interaction. However, the opsonized parasites 
appear to play a predominant role in promoting phagocytosis, 
involving the binding of C3b to the CR1 and CR3 and the 
binding of iC3b to the CR3 of the macrophage [74]. These 
interactions contribute to the establishment of infection and the 
evasion of the immune response required for the survival of the 
parasite within the macrophages, which possess potent 
microbicidal mechanisms. 
Phagocytized Leishmania initially localizes in the 
parasitophorous vacuole surrounded by the membrane of the 
host cell, which then fuses with the lysosome to form the 
phagolysosome that contains the proteolytic enzymes capable 
of lysing the parasites. Furthermore, parasite phagocytosis 
generates the macrophage effector elements, reactive oxygen 
species (mainly hydrogen peroxide = H
2
O
2
), which involve 
NADPH oxidase and superoxide dismutase, and reactive 
nitrogen species (nitric oxide = NO), which involve inducible 
nitric oxide synthase (iNOS) [77] [78] [79] [80] [81] [82] [83]. 
Recently, we observed that the protein-disulfide isomerase 
–NADPH oxidase interaction influences the phagocytosis of 
promastigotes of Leishmania chagasi [84]. 
The major mechanisms of evasion by Leishmania for 
parasite survival are as follows. Phagosome and lysosome 
fusion is inhibited, and the differentiation of the promastigotes 
to amastigotes is favored by LPG [85], which also sequesters 
hydroxyl radicals and superoxide anions [86]. Parasite lysis by 
lysosomal enzymes is hindered by gp63 [87] [88], the secreted 
factors [89] [90] and the cysteine proteinases of Leishmania 
[91]. 
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A decrease in the production of reactive oxygen species is 
desirable to the parasite survival, and this decrease is observed 
in Leishmania-infected macrophages [92] [93], which may 
involve the gp63 molecule [94]. Importantly, the opsonization 
mediated by the C3b and iC3b fragments and the related 
receptors CR1 and CR3 play an important role in these 
mechanisms, leading to significant decrease in the oxidative 
burst [95] [96]. Notably, the oxidative burst induced during the 
phagocytosis of amastigotes in macrophages is smaller than 
that induced by promastigotes [97]. 
Another leishmanicidal element, NO, is also modulated by 
infection, which may involve Leishmania 
glicoinositolphospholipid [98], the tyrosine phosphatase SHP-1 
[99] or the exposure of phosphatidyl serine observed 
specifically in the tissue-derived Leishmania amazonensis 
amastigotes, mimicking cell apoptosis [100]. NO is mainly 
considered to have a role in specific immunity, but it is very 
important in the nonspecific response, which functions within 
the first 24 hours of infection, as observed in mice deficient in 
iNOS activity [101] [102]. There is no known involvement of 
complement in the modulation of NO, but we have observed the 
inhibition of NO production by another nonspecific factor, the 
insulin-like growth factor –I, which is constitutively present in 
the skin and within macrophages [103]. 
Most of data presented here are derived from in vitro studies, 
but some in vivo experiments reinforce the role of complement 
in the progression of infection and lesion development rather 
than parasite control. The most relevant studies focus on the C3 
and C3R components. In hamsters transiently depleted of C3 by 
injection with cobra venom factor (CVF) and infected with L. 
chagasi, the inflammatory infiltrate and cell parasitism was 
analyzed during the initial 72 hours and at 240 days 
post-infection. The depletion of C3 led to a decrease in the 
amount of infected polymorphonuclear neutrophils (PMNs) 
and monocytes in the initial period and no detection of the 
whole parasite at 240 days in the liver or spleen, in contrast to 
patent infection in nondepleted animals [104]. In experimental 
cutaneous leishmaniasis, in BALB/c mice transiently depleted 
of C3 with CVF injection or permanently depleted of C3 with 
CVF gene transfection and infected with L. major, the lesion 
development was, respectively, considerably delayed or 
inhibited [105]. In the latter study, this outcome was attributed 
to the decreased migration of PMNs to the site of infection, but 
in the former study using hamsters, PMNs were detected at 
greater quantities after 2 hours of infection, which contradicts 
this supposition. The assumption of reduced PMN infiltration 
leading to lower infectivity is appropriate because in 
susceptible strains of mice, such as BALB/c, the PMNs are 
mainly necrotic and apoptotic and contribute to the 
development of the infection [106]. However, considering that 
the inhibition of the oxidative burst would occur when 
phagocytosis is mediated by CR1 and CR3 [95] [96], it may be 
more likely that in the absence of the engagement of CR1 and 
CR3 receptors during phagocytosis in C3-depleted animals, the 
process leads to the full activation of the oxidative burst with 
consequent parasite killing. The participation of CR3 was 
analyzed in CR3-depleted (CD11b knock out) BALB/c mice, in 
which the degree of L. major infection reached an intermediate 
size between the susceptible wild-type BALB/c mice and 
resistant C57BL/6 mice [107]. This phenotype was likely due 
to the preservation of complement activation and the 
phagocytosis of opsonized parasites through other complement 
receptors, such as CR1, leading to the partial modulation of the 
oxidative burst.  
In human visceral leishmaniasis, higher serum MBL levels 
were observed in active disease when compared with 
asymptomatic infected individuals or healthy controls [108]. 
Furthermore, a gene polymorphism in MBL2 that encodes 
human MBL was addressed in a case-control study in a 
population from northeastern Brazil, and it was observed that 
genotypes related to high serum levels of MBL were present at 
a significantly greater proportion among patients with active 
disease and with signs of severe manifestations [109]. These 
results suggest that the high MBL levels favor the development 
of infection. 
In the pathogenesis of glomerular lesions in visceral 
leishmaniasis, immune complex deposition with the 
consequent activation of the complement cascade and the 
resulting inflammation has been the accepted mechanism [110] 
[111]. However, we have recently shown that T cell-mediated 
immune mechanisms are apparently more important without 
any clear participation from complement activation [112]. 
We suggest that in leishmaniases, when complement is 
activated, the massive destruction of extracellular parasites 
likely occurs during the early phase of infection. However, the 
components of the complement system functioning in parasite 
opsonization and in the host macrophage-parasite interaction 
seem to contribute more to evasion, thus favoring progression 
of the infection. Furthermore, the complement system has 
seemingly marginal or no participation in the pathogenesis of 
glomerulitis in visceral leishmaniasis.  
IV. THE COMPLEMENT SYSTEM IN MALARIA 
In the course of Plasmodium infection, malaria antigens, 
either on the infected erythrocytes, released from schizont 
rupture, or in immune complexes with specific antibodies, can 
activate complement [113]. The hemoglobin and hematin that 
result from the intravascular lysis of Plasmodium 
falciparum-infected erythrocytes can also activate complement 
[114] [115]. The digestive vacuole, a membrane-bound 
organelle containing the malaria pigment hemozoin, which is 
released after infected erythrocyte rupture, activates the 
alternative complement cascade and the intrinsic clotting 
pathway. Activation is initiated by the intact organelle but not 
by isolated hemozoin. This is a protective function that allows 
the host to rapidly remove foreign material [116] [117]. 
The complement system is also a first line of defense against 
invasion by Plasmodium [118], but excessive complement 
activation may have deleterious consequences for the host 
(reviewed in [2]). Here, we will review some of the 
mechanisms that account for the host defense and how they 
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may result in complications that can lead to death. One element 
that has diverse roles in the development of infection and in 
various clinical manifestations of malaria is CR1. 
The invasion of erythrocytes by P. falciparum is a complex 
multistep process that involves multiple ligands on the 
merozoite surface and multiple erythrocyte receptors [8]. The 
majority of P. falciparum strains invade erythrocytes through 
interactions with sialic acid on glycophorins [119]. Most 
recently, it was reported that CR1 is a sialic acid-independent 
invasion receptor of P. falciparum on human erythrocytes [120]. 
The ligand for CR1 on the erythrocyte surface is PfRh4, and the 
CR1-PfRh4 interaction mediates the functional sialic 
acid–independent pathway for the entry of P. falciparum into 
human erythrocytes [121]. Nevertheless, additional parasite 
ligands may exist [119]. The region within CR1 that is 
recognized by the P. falciparum adhesin PfRh4 is within the 
complement control protein modules 1 to 3 (CCP1-3) of CR1, 
and other regions of CR1 are unlikely to be involved. The 
binding of PfRh4 to CR1 does not affect its C3b/C4b binding 
capability but does inhibit the convertase decay-accelerating 
activity of CR1, whereas there is no effect on the factor 
H-mediated decay-accelerating activity [118]. 
CR1 and other complement control proteins, including CD55 
and CD59, protect erythrocytes from hemolysis (reviewed in 
[18]). In vivo, the binding of circulating immune complexes to 
erythrocytes via CR1 does not induce erythrocyte destruction, 
whereas the formation of immune complexes at other sites 
promotes hemolysis and/or clearance. Erythrocytes are spared 
because of a process known as the transfer reaction, in which 
the engagement of CR1-bound immune complexes by 
macrophage Fc receptors leads to proteolytic cleavage of CR1, 
resulting in the loss of CR1 and the associated immune 
complexes from the surface of erythrocytes [122].  
DAF or glycophorin A-bound immune complexes consisting 
of multiple antibodies, with or without complement, are also 
transferred from erythrocytes to model macrophages. DAF is 
lost from the erythrocyte during this transfer process. However, 
when immune complexes are bound to glycophorin A, either 
the transfer of immune complexes to macrophages or the 
phagocytosis of the erythrocyte by macrophages can occur 
[18]. 
In a study of infected Malian children [10], circulating 
immune complex levels correlated with malaria severity, 
indicating that the erythrocyte CR1 removal system was 
overburdened. Low levels of erythrocyte CR1 copy numbers 
were found in children with severe malaria. The circulating 
immune complexes remaining in the circulation became 
deposited in internal organs, causing renal failure or coma.  
Rosetting is an adhesion property in which the erythrocytes 
infected with late-stage trophozoites bind to uninfected 
erythrocytes to form clumps of cells [123], which can 
potentially obstruct small capillaries [8].  
When P. falciparum merozoites invade erythrocytes, they 
make changes to the cytoskeleton and insert parasite-derived 
proteins into and onto the erythrocyte membrane. One such 
protein is the erythrocyte membrane protein PfEMP1, which is 
encoded by a specific var gene [124] [125]). Rosetting is 
mediated through the interaction between PfEMP1 expressed 
on the surface of infected erythrocytes and several receptors on 
endothelial cells and uninfected erythrocytes, such as blood 
group antigens A and B, serum components, 
glycosaminoglycans and CR1 [12]. CR1 acts as the major 
rosetting receptor in P. falciparum infection [126]. 
The CR1 region required for rosetting is short consensus 
repeat modules (SCRs) 10 and 17 [121]. The regions that bind 
to PfEMP-1 and PfRh4 may be distinct within CR1 [127].  
The interaction between PfEMP1 and CR1 likely provides an 
advantage to the parasite that remains sequestered in the 
microcapillaries, avoiding destruction in the spleen and liver 
[15]. 
The possible mechanisms by which rosetting is thought to 
contribute to severe malaria are increased microvascular 
obstruction to blood flow [128], impaired tissue perfusion [128], 
elevated parasite densities, favoring invasion of the merozoites 
[129] and immune evasion [130]. High levels of CR1 are more 
likely to form rosettes that contribute to sequestration in brain 
capillaries and other vital organs, leading to the blockage of 
blood flow and to cerebral malaria [124]. The greater the 
number of CR1 molecules per erythrocyte, the greater the 
tendency to form rosettes [124]. Although other erythrocyte 
molecules, such as blood group A, might be involved in 
rosetting [131], CR1 appears to be the major component [9]. 
High levels of CR1 also carry more immune complexes that 
can interact with monocytes and endothelial cells to produce 
pro-inflammatory mediators [9]. However, varied results have 
been obtained in population surveys on the association between 
malaria and genetic variants of CR1 that influence the levels of 
CR1 expression [12]. Low levels of erythrocyte CR1 are more 
likely to correspond to complement-mediated damage and the 
removal of erythrocytes in the spleen, leading to severe anemia 
[132].  
The polymorphisms associated with erythrocyte CR1 
deficiency confer protection against severe malaria. Studies in 
Papua New Guinea [11] showed that this deficiency occurs in 
up to 80% of healthy individuals from the malaria-endemic 
regions and that rosetting may be an important parasite 
virulence phenotype that should be a target for drug and 
vaccine development.  
Severe malaria-associated anemia (SMA), one of the 
complications of malaria, cannot be explained by the direct 
lysis of infected erythrocytes, as only a small proportion of 
erythrocytes become infected [18]. Additionally, patients 
treated for P. falciparum malaria continue to experience 
erythrocyte destruction after treatment [133]. Therefore, 
additional mechanisms act to destroy uninfected erythrocytes 
during infection [8]. C3 and IgG deposition on erythrocytes, 
reduced CR1 and DAF, and pronounced splenic enlargement 
were observed in children with severe P. falciparum anemia, 
suggesting that antibodies, complement, and phagocytosis may 
be involved in erythrocyte loss [18].  
The binding of antibodies, immune complexes, and 
complement to erythrocytes may lead to the following: 
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hemolysis by MAC, erythrophagocytosis by fixed tissue 
macrophages in the liver and spleen, or removal of immune 
complexes or antibodies bound to erythrocytes by transfer to 
macrophages. Under normal conditions, erythrocytes are 
protected from hemolysis by the action of complement control 
proteins, such as CR1. The transfer reaction spares the 
erythrocytes from being removed and destroyed by fixed tissue 
macrophages [18].  
Waitumbi et al. [134] have demonstrated increased levels of 
circulating immune complexes in patients with SMA compared 
with control subjects. Children with SMA manifest lower levels 
of CR1 and CD55 than children with uncomplicated malaria or 
uninfected children [8] [132] [134]. This decrease in the levels 
of complement regulatory proteins does not appear to have a 
genetic basis because after treatment for malaria and blood 
transfusions, these patients exhibited a normalization of the 
CR1 and CD55 levels [8] [132]. The decline in CR1 on 
erythrocyte surfaces has been shown to be associated with 
increased C3b deposition [2] [135] and is thought to result from 
the increased proteolysis of CR1-bound immune complexes 
(transfer reaction) by phagocytic cells during the process of 
removing immune complexes from circulation. Young children 
may be more susceptible to SMA because of their lower levels 
of erythrocyte complement regulatory proteins [134].  
Individuals with low levels of CD55 and CD35 on 
erythrocytes, either as a result of repeated malaria infections or 
due to physiologic changes in expression with age, are at high 
risk for SMA due to the formation of immune complexes or 
complement activation during malaria infection (reviewed in 
Stoute [8]). When CR1 and CD55 deficiency reach a certain 
level, the erythrocytes lose their ability to control complement 
activation and remove immune complexes from circulation. In 
this way, C3b and immune complexes lead to the destruction of 
erythrocytes by either phagocytosis and/or 
complement-mediated lysis [132]. 
The pathogenesis of CM is complex, and it may be the result 
of the interplay between the sequestration of infected 
erythrocytes in the brain microvasculature, the 
pro-inflammatory response of the host, and the virulence of the 
parasite variant (reviewed in [125]).  
The role of CR1 in CM pathogenesis has also been 
investigated. A population survey of the association between 
CR1 genetic variants and malaria reported some conflicting 
findings [12]. In Papua New Guinea, Cockburn et al. [11] found 
that intermediate CR1 levels had a protective effect against 
severe malaria. In contrast, Nagayasu et al. [136] reported that 
deficiencies in CR1 levels were significantly more common in 
severe malaria. In Thailand, Teeranaipong et al. [126] studied 
17 different polymorphisms and identified one in the promoter 
region of CR1 that was associated with protection against CM 
and increased erythrocyte CR1, whereas low levels of CR1 
were not associated with protection against CM, pointing to a 
role for CR1 in CM. If erythrocytes with high CR1 levels can 
plug brain capillaries, the immune complexes carried by these 
erythrocyte could also interact with monocytes and endothelial 
cells, leading to the production of local inflammatory mediators, 
which can cross the blood-brain barrier [8] [9]. In a 
hyperendemic region of India, Rout et al. [12] found that 
increased erythrocyte CR1 levels, as determined by genotyping, 
were associated with CM.  
CM and SMA are epidemiologically and clinically distinct; 
children with SMA are generally younger than children with 
CM [8]. Nevertheless, erythrocyte complement regulatory 
proteins have been implicated in the pathogenesis of both [134]. 
Patients with CM tend to have higher levels of erythrocyte 
complement regulatory proteins than patients with SMA: older 
children and adults may be at a higher risk of CM because of 
increasing levels of erythrocyte complement regulatory 
proteins with age, whereas young children may be more 
susceptible to SMA because of their lower levels of RBC 
complement regulatory proteins. The levels of expression of 
CR1 and CD55 on erythrocytes vary with age in both endemic 
and nonendemic countries. The levels are low in young 
children and increase into adulthood, and in regions with 
intense malaria transmission, compared to nonendemic areas, 
the changes in levels could help to explain the epidemiological 
differences between CM and SMA [9] [134]. 
Experimental CM in mice infected with P. berghei has been 
a model for studying the role of complement in the 
development and progression of malaria and CM. In this model, 
the resistance to CM development in naturally C5-deficient 
mice suggests the involvement of C5 [137] [138], but the 
complement anaphylatoxin receptor appears to not have a role 
in pathogenesis [139]. In fact, the critical role of C5 in ECM is 
apparently mediated at the level of C5b and MAC formation 
instead of complement anaphylatoxins. 
In another study, the deletion of C4, Factor B, or C3 was 
shown to have no effect on the susceptibility to experimental 
CM, suggesting no involvement of the classical or alternative 
pathways and C5 convertases in experimental CM development 
and progression [140]. It was suggested that the activation of 
C5 in experimental CM likely occurs via the coagulation 
enzymes of the extrinsic protease pathway, as factors Xa, IXa, 
and XIa can cleave both C3 and C5 to generate C3a and C5a [5] 
in the absence of C5 convertases [141].  
During P. falciparum infection in pregnancy, parasitized 
erythrocytes bind to chondroitin sulfate A and sequester it in 
the placental intervillous space, resulting in placental malaria 
[142]. Women living in areas of stable transmission develop 
antibodies that block sequestration after successive pregnancies, 
and primigravidae or HIV-infected individuals are the most 
susceptible to adverse outcomes of placental malaria [143]. 
Placental malaria can lead to life-threatening consequences for 
both the mother and the fetus, such as severe maternal anemia, 
spontaneous abortion, stillbirth, and low birth weight at 
delivery [143]. 
During pregnancy, complement activation is augmented and 
is 50% more augmented in primigravidae women than in 
uninfected pregnant women [138]. This augmentation protects 
against infections and maintains a tolerant state towards the 
semi-allogeneic fetus [144]. The complement regulatory 
proteins, such as CD55, CD59, and CD46, expressed in the 
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placenta may be overwhelmed by the excess complement 
activation during PM, contributing to placental injury 
(reviewed in [2]). A model of immunopathogenesis during 
malaria in pregnancy has been suggested, in which infected 
erythrocytes present in the placental intervillous space 
contribute to the increased production of C5a and the 
immunologic activation of fetal trophoblasts and maternal 
mononuclear cells [143]. In this model, C5a exacerbates the 
inflammatory reaction of the placenta and deregulate 
angiogenesis, impairing the adequate vascularization of the 
placenta, via an inflammation-independent pathway. The 
complement factor C5a would therefore constitute a central 
initiator of poor birth outcomes associated with placental 
malaria.  
An association between reduced birth weight and higher 
levels of terminal complement complex was also found in 
placental blood, suggesting a role for complement activation as 
one of the underlying mechanisms. The release of 
anaphylatoxins C3a and C5a would activate monocytes and 
other inflammatory cells in the placenta, leading to the 
secretion of abnormal levels of proinflammatory cytokines 
[145]. 
The balance between the activation and regulation of the 
complement system may be an important determinant of the 
severity and outcome of malaria. When in excess, activation 
may be deleterious to the host. However, when the parasite 
evades or subverts the immune system, such as by inhibiting 
complement activation and effector functions or using 
receptors to facilitate entry into host cells, their ability to 
survive will increase. 
V. BOX 1. SCHISTOSOMA SPP AND SCHISTOSOMIASES 
Schistosomiases are diseases caused by various trematode 
species of the genus Schistosoma. Schistosoma mansoni and S. 
japonicum are most prevalent, but S. mansoni is the most 
widespread species infecting 83.3 million individuals 
worldwide [4], which we will consider in this review. 
Freshwater snails of the genus Biomphalaria function as the 
intermediary host. In humans, the definitive host, adult worms 
that live in the mesenteric veins lay their eggs, which reach the 
circulation and the intestinal lumen. When the eggs reach 
freshwater in the environment, they transform into miracidium 
that may infect the snails. The infected snails liberate the 
parasites in the form of cercariae that may penetrate the human 
skin that is exposed to contaminated water. Within the 
mammalian host, they transform in the skin into schistosomula 
that migrate to lung and liver. As sexually mature adult worms, 
the males and females form pairs and localize to the mesenteric 
veins around the intestinal wall, where they remain to lay eggs 
for years or decades. From the moment of penetration of the 
skin to the final localization in the mesenteric vein, the cycle 
takes approximately four to six weeks [21]. The symptoms in 
humans derive from the reactions to the various stages of the 
life cycle of the parasite [25]. The infected individuals may 
present skin erythema during the penetration of the cercariae, 
fever and pulmonary symptoms during the period when the 
schistosomula circulate through the lung. The localization of 
the adult worms in the mesenteric vein initiates the intestinal 
phase, which is usually asymptomatic. Some of the eggs reach 
the liver, inducing the formation of granulomas and ensuing 
hepatointestinal schistosomiasis. Granulomas may affect the 
local circulation, which may result in portal hypertension, 
leading to the hepatosplenic phase. 
VI. BOX 2. LEISHMANIA SPP AND LEISHMANIASES 
Leishmaniases are diseases caused by various species of 
protozoan of the genus Leishmania that are transmitted by 
phlebotomine sandflies of the genus Lutzomyia and 
Phlebotomus to vertebrate hosts with the incidence of two 
million new cases per year. They are zoonotic diseases, and 
diverse mammalian species can be infected that constitute 
reservoirs of Leishmania. Humans become infected when they 
live in or visit areas that are endemic for the parasite [146]. 
Leishmania are present in phlebotomine sandflies as 
promastigotes (elongated forms of the protozoa with an 
external flagellum) and in the vertebrate host as amastigotes 
(round forms without any external flagellum) [147]. Visceral 
and tegumentary manifestations have been observed in humans; 
visceral leishmaniasis is caused by Leishmania (L.) donovani 
and L. (L.) infantum, and tegumentary leishmaniasis is caused 
by approximately 15 species of parasites, with L. (L.) major, L. 
(L.) aethiopica, L. (Viannia) braziliensis, L. (L.) amazonensis, 
and L. (V.) guyanensis being the more prevalent [148]. Patients 
with active visceral leishmaniasis present fever, 
hepatosplenomegaly, pancytopenia, and 
hypergammaglobulinemia. Currently, severe cases involving 
secondary infections, hemorrhage, pancytopenia, and liver 
dysfunction are increasing with consequently high lethality. 
The manifestations of tegumentary leishmaniasis are variable, 
from localized cutaneous to mucosal forms, and also present as 
disseminated or diffuse forms or as leishmaniasis recidiva cutis 
[148], and some forms correspond to particular species. 
VII. BOX 3. PLASMODIUM SPP AND MALARIA  
Malaria is a disease caused by various species of protozoan 
of the genus Plasmodium. In humans, the more prevalent 
species are Plasmodium falciparum and P. vivax and less 
frequently, P. malariae and P. ovale. Recently, a growing 
number of human infections with P. knowlesi, a species 
typically infecting Old World monkeys, have been reported 
[149] [150]. The World Health Organization (WHO) [151] 
estimates that 3.3 billion people worldwide were at risk of 
malaria in 2010, with between 154 and 289 million cases of 
clinical disease and between 490,000 and 836,000 deaths 
caused by malaria. The majority of deaths (86%) was in 
children less than 5 years old living in sub-Saharan Africa [151]. 
The life cycle is complex, and in man, it begins with the 
inoculation of sporozoites by the Anopheles mosquito during 
its blood meal. These sporozoites invade the hepatocytes and 
begin development by multiplying by schizogony (liver stage). 
After a period of 5 to 14 days, the schizonts develop into 
thousands of merozoites that are delivered into the bloodstream, 
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where they invade erythrocytes, initiating the blood stage. 
Within the erythrocytes, each merozoite differentiates into a 
trophozoite that matures and divides, generating a schizont that 
develops to up to 32 merozoites within 48 hours, which reinfect 
new erythrocytes to maintain the cycle. Some merozoites may 
develop into sexual forms, the male or female gametocytes. 
When a female Anopheles mosquito ingests the gametocytes 
during a blood meal, it becomes infected. Passing through 
fertilization within the insect, the sporozoites are generated that 
migrate to the salivary gland prepared to start a new infection in 
man when the mosquito bites the host. The initial symptoms 
may be nonspecific headache, fever, and shivering, but the 
characteristic feature of the subsequent phase is the paroxystic 
occurrence of sudden shivering/coldness followed by fever 
occurring every two or three days depending on the parasite 
species.  
The most severe clinical forms of malaria are caused by P. 
falciparum, especially in nonimmune adults, children, and 
pregnant women. The WHO estimates that in 2010, there were 
between 490,000 and 836,000 malaria-related deaths [151]. 
The overwhelming majority of malaria-associated mortality is 
caused by P. falciparum, and most deaths occur because of 
complications, such as cerebral malaria (CM), severe malarial 
anemia (SMA) and placental malaria (PM) (reviewed in [2]). 
SMA is usually observed in children under 5 years of age living 
in areas with intense transmission in Africa (reviewed in [8]). In 
holoendemic areas, most cases of SMA occur a few months 
after birth, when the transplacental immunity begins to wane, 
up to 24 months of age [134]. CM has a fatality rate of 15–30%, 
and more than 10% of the children who recover from CM have 
ongoing neurological complications, such as cognitive 
impairment [125] [140]. In holoendemic areas, SMA is more 
common than CM. However, in low transmission areas, SMA 
is less common [134]. In stable transmission areas, PM is most 
common in primigravidae or pregnant women with impaired 
acquired immunity [143].  
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